Bernstein Upgrades Biogen (BIIB) to Outperform
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $197.19 -1.26%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Join SI Premium – FREE
Bernstein upgraded Biogen (NASDAQ: BIIB) from Market Perform to Outperform with a price target of $385.00 (from $436.00).
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $300.03 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- Constellation Brands (STZ) PT Lowered to $157 at Jefferies
- Corbus Pharmaceuticals (CRBP) PT Lowered to $34 at Mizuho
Create E-mail Alert Related Categories
Analyst PT Change, Hot Upgrades, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
